Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Olon S.p.A., Salix deal

Salix acquired worldwide rights to Olon's IP relating to amorphous rifaximin. The IP includes a pending

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE